Skip to main content
ELI LILLY & Co logo

ELI LILLY & Co - Investor Relations & Filings

Listed
Ticker · LLY ISIN · US5324571083 LEI · FRDRIPF3EKNDJ2CQJL29 US Manufacturing
Open in API
Filings indexed 3,885 across all filing types
Latest filing 2026-06-23 Annual Report
Country US United States of America
Listing US LLY · 23 venues

About ELI LILLY & Co

https://www.lilly.com/

Eli Lilly and Company is a global, research-based medicine company that discovers, develops, manufactures, and sells pharmaceutical products. The company focuses on creating treatments in key therapeutic areas, including diabetes, obesity, immunology, oncology, and neuroscience. Leveraging biotechnology and chemistry, it develops medicines for some of the world's most significant health challenges. Historically known for the commercialization of insulin, the company continues to be a major provider of therapies for chronic diseases. Its stated purpose is to unite caring with discovery to create medicines that make life better for people around the world.

Recent filings

Filing Released Lang Actions
11-K
Annual Report Classification · 95% confidence The document is a United States SEC filing labeled as FORM 11-K, which is a specific annual report filed pursuant to Section 15(d) of the Securities Exchange Act of 1934. It covers the fiscal year ended December 31, 2025. The content includes detailed financial statements and supplemental schedules of The Lilly Employee 401(k) Plan and The Savings Plan for Lilly Affiliate Employees in Puerto Rico, including audited financial statements by Ernst & Young LLP. The length (approximately 39,647 characters) and detailed financial data confirm this is the full report, not merely an announcement or certification. FORM 11-K is a type of annual report focused on employee benefit plans. Given the content and SEC form type, this filing is best categorized under Annual Report (10-K) for classification purposes related to official yearly reports covering company activity and full financial performance of a specific plan. FY 2025
2026-06-23 English
Goldman Sachs 47th Annual Global Healthcare Conference 2026
Call Transcript Classification · 100% confidence
2026-06-09 English
American Diabetes Association (ADA) 86th Scientific Sessions
Call Transcript Classification · 100% confidence
2026-06-07 English
Bernstein 42nd Annual Strategic Decisions Conference
Call Transcript Classification · 100% confidence
2026-05-28 English
8-K
Capital/Financing Update Classification · 98% confidence The document is a Form 8-K “Current Report” filed under the Securities Exchange Act, specifically reporting the completion of Eli Lilly’s offering of various floating rate and fixed rate notes. This constitutes a financing activity (debt issuance), not an earnings release or management discussion. Therefore it falls under the Capital/Financing Update category.
2026-05-20 English
SD
Report Publication Announcement Classification · 78% confidence The document is a short SEC “Form SD” specialized disclosure (Conflict Minerals) filing for the year ended December 31, 2025. It contains no substantive financial statements; rather, it states that the detailed Conflict Minerals Report is attached as an exhibit and available via a link. Under the “Menu vs Meal” rule, such brief filings that announce publication of a report and provide a link or exhibit are classified as Report Publication Announcements (RPA).
2026-05-11 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.